Colinz Laboratories Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 621096, "name": "Colinz Labs", "stock_name": "Colinz Labs", "full_name": "Colinz Laboratories Ltd", "name_url": "stocks-analysis/colinz-labs", "exchange": 0, "exchangecode": "", "primexch": 0, "country_id": 34, "currency": "INR", "cmp": "55.90", "chg": -2.92, "chgp": "-4.96%", "dir": -1, "prev_price": "58.82", "mcapval": "15.00 Cr", "mcap": "Micro Cap", "scripcode": 531210, "symbol": "", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE923C01011", "curr_date": "Jun 10, 03:30 PM", "curr_time": "18:44 PM", "last_traded_at": "Jun 10, 03:30 PM IST", "bse_nse_vol": "1.94 k", "exc_status": "Active", "traded_date": "Jun 10, 2026", "traded_date_str": "2026 06 10", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/colinz-labs-621096-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Colinz Laboratories Ltd Upgraded to Hold on Attractive Valuation and Stable Fundamentals", "link": "https://www.marketsmojo.com/news/stock-recommendation/colinz-laboratories-ltd-upgraded-to-hold-on-attractive-valuation-and-stable-fundamentals-4043342", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ColinzLaborator_mojoScore_4043342.png", "date": "2026-06-10 08:04:44", "description": "Colinz Laboratories Ltd has seen its investment rating upgraded from Sell to Hold, driven primarily by an improved valuation profile and steady financial trends despite flat quarterly results. The micro-cap pharmaceutical company’s recent performance and comparative metrics have prompted a reassessment of its quality, valuation, financial trend, and technical outlook, culminating in a more favourable stance by analysts." }, { "title": "Colinz Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness", "link": "https://www.marketsmojo.com/news/stocks-in-action/colinz-laboratories-ltd-valuation-shifts-signal-renewed-price-attractiveness-4043168", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ColinzLaborator_valuationdot_4043168.png", "date": "2026-06-10 08:00:58", "description": "Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift favourably, prompting an upgrade in its Mojo Grade from Sell to Hold. Despite a recent 4.98% dip in share price, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a more attractive entry point relative to its historical and peer averages, signalling potential value for discerning investors." }, { "title": "Colinz Laboratories Ltd Downgraded to Sell Amid Mixed Technicals and Fair Valuation", "link": "https://www.marketsmojo.com/news/stock-recommendation/colinz-laboratories-ltd-downgraded-to-sell-amid-mixed-technicals-and-fair-valuation-4035379", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ColinzLaborator_mojoScore_4035379.png", "date": "2026-06-04 08:05:40", "description": "Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 3 June 2026. This shift reflects a complex interplay of technical improvements, valuation adjustments, and subdued financial trends, prompting a reassessment of the stock’s attractiveness despite recent price gains." }, { "title": "Colinz Laboratories Ltd Valuation Shifts Signal Changing Market Sentiment", "link": "https://www.marketsmojo.com/news/stocks-in-action/colinz-laboratories-ltd-valuation-shifts-signal-changing-market-sentiment-4035107", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ColinzLaborator_valuationdot_4035107.png", "date": "2026-06-04 08:00:26", "description": "Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation grade downgraded from attractive to fair, reflecting a notable shift in price attractiveness despite robust long-term returns. The company’s price-to-earnings (P/E) ratio now stands at 30.57, signalling a more cautious stance among investors amid evolving market dynamics and sector comparisons." }, { "title": "Colinz Laboratories Ltd Upgraded to Hold as Technicals Improve Amid Flat Financials", "link": "https://www.marketsmojo.com/news/stock-recommendation/colinz-laboratories-ltd-upgraded-to-hold-as-technicals-improve-amid-flat-financials-4032917", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ColinzLaborator_mojoScore_4032917.png", "date": "2026-06-03 08:04:05", "description": "Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 2 June 2026. This revision reflects a combination of improved technical indicators, attractive valuation metrics, and a cautiously optimistic financial trend despite flat recent results. The upgrade signals a more balanced outlook for investors amid mixed fundamental signals and a strengthening price momentum." }, { "title": "Colinz Laboratories Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals", "link": "https://www.marketsmojo.com/news/stock-recommendation/colinz-laboratories-ltd-upgraded-to-sell-on-technical-improvements-despite-weak-fundamentals-4029917", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ColinzLaborator_mojoScore_4029917.png", "date": "2026-06-02 08:10:58", "description": "Colinz Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 1 June 2026, driven primarily by a shift in technical indicators despite persistent fundamental challenges. The pharmaceutical company’s stock price rose 4.99% on 2 June 2026, reflecting renewed investor interest amid a mildly bullish technical trend, even as financial performance remains flat and valuation metrics suggest cautious optimism." }, { "title": "Colinz Laboratories Declines 1.68%: Downgrade and Mixed Q4 Results Shape the Week", "link": "https://www.marketsmojo.com/news/stocks-in-action/colinz-laboratories-declines-168-downgrade-and-mixed-q4-results-shape-the-week-3971730", "imagepath": "", "date": "2026-05-02 16:05:35", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>27 Apr:</strong> Stock opens at Rs.45.00 after downgrade announcement</p>\n <p><strong>28 Apr:</strong> Mojo Grade downgraded to Strong Sell amid weak fundamentals</p>\n <p><strong>29 Apr:</strong> Stock rallies 4.00% on increased volume</p>\n <p><strong>30 Apr:</strong> Q4 FY25 results reveal profit surge but revenue stagnation; stock dips 3.64%</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.46.89</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div cla..." }, { "title": "Are Colinz Laboratories Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-colinz-laboratories-ltd-latest-results-good-or-bad-3970719", "imagepath": "", "date": "2026-04-30 19:14:28", "description": "Colinz Laboratories Ltd's latest financial results for Q4 FY25 present a complex picture of operational performance. The company reported net sales of ₹1.75 crores, reflecting a sequential growth of 22.38% from the previous quarter and a year-on-year increase of 20.69%. This growth in sales is notable, especially considering the broader context of a 14.30% decline in annual sales for FY25 compared to FY24.\n\nIn terms of profitability, the net profit for Q4 FY25 was ₹0.17 crores, marking a significant sequential increase of 112.50%. The profit after tax margin improved to 9.71%, up from 5.59% in the previous quarter, indicating better operational efficiency and cost management. However, this improvement must be viewed cautiously, as it comes against a backdrop of declining annual revenues and a low return on equity (ROE) of 4.96%, which raises concerns about the company's ability to generate sustainable share..." }, { "title": "Colinz Laboratories Q4 FY25: Profit Surge Masks Underlying Revenue Concerns", "link": "https://www.marketsmojo.com/news/result-analysis/colinz-laboratories-q4-fy25-profit-surge-masks-underlying-revenue-concerns-3970201", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ColinzLaborator_quaterlyResult_3970201.png", "date": "2026-04-30 09:47:10", "description": "Colinz Laboratories Ltd., a micro-cap pharmaceutical formulations manufacturer, reported net profit of ₹0.17 crores for the quarter ended March 2026 (Q4 FY25), marking a 112.50% surge on a quarter-on-quarter basis from ₹0.08 crores in Q3 FY25. On a year-on-year basis, the company posted a modest 13.33% growth from ₹0.15 crores in Q4 FY24. However, this profit improvement comes against a backdrop of declining annual revenues and persistent operational challenges that raise questions about the sustainability of this performance." } ], "total": 612, "sid": "621096", "stock_news_url": "https://www.marketsmojo.com/news/colinz-laboratories-621096" }, "announcements": [ { "caption": "Clarification sought from Colinz Laboratories Ltd", "datetime": "01-Jun-2026", "details": "The Exchange has sought clarification from Colinz Laboratories Ltd on June 1 2026 with reference to significant movement in price in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.<BR><BR>The reply is awaited.", "source": "BSE" }, { "caption": "Submission Of Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations 2011", "datetime": "26-May-2026", "details": "Dear Sir Submitting the Dislosure under Regulatiom 29(2) under SEBI (SAST) Regulation 2011. Sumitted by Vijaya Mani the Promoter and Director of the Company anaingt sell of her Equity Shares. Kindly take the note of the same. For COlinz Labs Ltd Ganesh Chitte CFO", "source": "BSE" }, { "caption": "Submission Of Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations 2011", "datetime": "26-May-2026", "details": "Dear Sir Submitting herewith the Disclosure 29(1) as required under SEBI (SAST) Regulations 2011 submitted by Mr Padam Dugar the acquirer . Kindly take the same on records. For Colinz Labs Ltd Ganesh Chitte CFO", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "No <strong>Dividend</strong> history available", "data": [] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

27 Apr: Stock opens at Rs.45.00 after downgrade announcement

28 Apr: Mojo Grade downgraded to Strong Sell amid weak fundamentals

29 Apr: Stock rallies 4.00% on increased volume

30 Apr: Q4 FY25 results reveal profit surge but revenue stagnation; stock dips 3.64%

Week Open

Rs.46.89

Week Close

Read full news article

Are Colinz Laboratories Ltd latest results good or bad?

2026-04-30 19:14:28

Colinz Laboratories Ltd's latest financial results for Q4 FY25 present a complex picture of operational performance. The company reported net sales of ₹1.75 crores, reflecting a sequential growth of 22.38% from the previous quarter and a year-on-year increase of 20.69%. This growth in sales is notable, especially considering the broader context of a 14.30% decline in annual sales for FY25 compared to FY24. In terms of profitability, the net profit for Q4 FY25 was ₹0.17 crores, marking a significant sequential increase of 112.50%. The profit after tax margin improved to 9.71%, up from 5.59% in the previous quarter, indicating better operational efficiency and cost management. However, this improvement must be viewed cautiously, as it comes against a backdrop of declining annual revenues and a low return on equity (ROE) of 4.96%, which raises concerns about the company's ability to generate sustainable share...

Read full news article

Colinz Laboratories Q4 FY25: Profit Surge Masks Underlying Revenue Concerns

2026-04-30 09:47:10

Colinz Laboratories Ltd., a micro-cap pharmaceutical formulations manufacturer, reported net profit of ₹0.17 crores for the quarter ended March 2026 (Q4 FY25), marking a 112.50% surge on a quarter-on-quarter basis from ₹0.08 crores in Q3 FY25. On a year-on-year basis, the company posted a modest 13.33% growth from ₹0.15 crores in Q4 FY24. However, this profit improvement comes against a backdrop of declining annual revenues and persistent operational challenges that raise questions about the sustainability of this performance.

Read full news article